Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y1)- and GRP-Receptors-An Improvement for Breast Cancer Imaging?
Heterobivalent peptidic ligands (HBPLs), designed to address two different receptors independently, are highly promising tumor imaging agents. For example, breast cancer has been shown to concomitantly and complementarily overexpress the neuropeptide Y receptor subtype 1 (NPY(Y1)R) as well as the ga...
Saved in:
Main Authors: | Alicia Vall-Sagarra (Author), Shanna Litau (Author), Clemens Decristoforo (Author), Björn Wängler (Author), Ralf Schirrmacher (Author), Gert Fricker (Author), Carmen Wängler (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2018-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy
by: Benedikt Judmann, et al.
Published: (2020) -
Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFA<i>lin</i>-Modified Peptidic Radioligands Targeting Both Integrin α<sub>v</sub>β<sub>3</sub> and the MC1 Receptor-Suitable for the Specific Visualization of Melanomas?
by: Xia Cheng, et al.
Published: (2021) -
Truncated NPY-based NPY(Y1)R-specific radiopeptides: Improved in vivo PET tumor imaging by application of peptidase inhibitors
by: Benedikt Judmann, et al.
Published: (2024) -
Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11
by: Benedikt Judmann, et al.
Published: (2023) -
Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
by: Helen Damerow, et al.
Published: (2022)